Market Overview

UPDATE: Deutsche Bank Downgrades IPC The Hospitalist Company to Hold Following Q2 Results

Related IPCM
US Stock Futures Flat, Apple In Focus
IPC Hires New Senior Vice President of Sales And Marketing

In a report published Friday, Deutsche Bank analyst Darren Lehrich downgraded the rating on IPC The Hospitalist Company (NASDAQ: IPCM) from Buy to Hold, but reiterated the $48.00 price target.

In the report, Deutsche Bank noted, “IPCM's Q2 results were slightly below expectations due primarily to a sequential deceleration in encounter (volume) growth and flattish yoy margins. While 13.5% revenue and EBITDA growth is respectable, we believe IPCM's forward trading multiple (20.5x P/E and 11.4x EV/EBITDA) demands slightly more, and thus an earnings miss with decelerating fundamental trends seems disappointing. While we expect IPCM's EPS growth to track 14-15% over the next 24 months, we believe decelerating encounter growth (due to weaker hospital census and modestly higher physician turnover) poses some risk to the story. Moving to Hold on a more balanced risk/reward equation.”

IPC The Hospitalist Company closed on Thursday at $52.12.

Latest Ratings for IPCM

Jul 2014Credit SuisseMaintainsNeutral
Jun 2014Credit SuisseMaintainsNeutral
Apr 2014Wells FargoUpgradesMarket PerformOutperform

View More Analyst Ratings for IPCM
View the Latest Analyst Ratings

Posted-In: Darren Lehrich Deutsche BankAnalyst Color Downgrades Analyst Ratings


Related Articles (IPCM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters